- [Resource Hub](/)
- [Resource](/?resource-type=poster#library)
- Simultaneous assessment of PD-L1 and IRF1 expression on breast cancer circulating tumor cells

# Simultaneous assessment of PD-L1 and IRF1 expression on breast cancer circulating tumor cells

PD-L1 staining on its own cannot separate a tumor cell responding to interferon-gamma from one expressing PD-L1 for another reason; this AACR 2018 poster reports a 6-marker assay that reads PD-L1 together with its upstream regulator IRF1 on the same breast cancer circulating tumor cell.

Presented by RareCyte and University of Washington.

Read or download to see:

- A 6-marker panel places PD-L1 and nuclear IRF1 on the same circulating tumor cell. Buffy coat was separated from 7.5 mL of blood by AccuCyte, stained for pan-cytokeratin, EpCAM, CD45, PD-L1, IRF1 and a nuclear dye, then scanned on CyteFinder, with CTCs identified by cytokeratin and/or EpCAM positivity and negative CD45 staining.

- Two CTC models separate interferon-gamma-driven PD-L1 from PD-L1 expressed without it. A549 cells cultured overnight with 10 ng/mL interferon-gamma showed PD-L1 staining and strong nuclear IRF1, while unstimulated MDA-MB-231 cells showed high PD-L1 with low to absent nuclear IRF1 — a pattern that may identify PD-L1 expression not driven by interferon-gamma signaling.

- In patient CTCs, high-PD-L1 cells carried 2.7-fold more nuclear IRF1 than low-PD-L1 cells. With the PD-L1 threshold set at the upper 95% confidence interval of unstimulated A549 cells, high-PD-L1 CTCs from two breast cancer patients had a mean 2.7-fold higher nuclear IRF1 mean fluorescence intensity than low-PD-L1 CTCs, ranging from 1.4 to 3.3; the poster presents this simultaneous readout as feasible for non-invasive assessment.

[Download poster](https://cdn.sanity.io/files/s3p6uqps/production/5ee59a52aebd07afa411ffafb41049a4f8919b3a.pdf)

Your browser doesn’t support embedded PDFs.
[Download the poster](https://cdn.sanity.io/files/s3p6uqps/production/5ee59a52aebd07afa411ffafb41049a4f8919b3a.pdf) to view it.

[Back to all resources](/#library)
## Related resources
[Publication](https://doi.org/10.1200/JCO.2026.44.16_suppl.5041) CyteFinder Journal of Clinical Oncology 2026
### Clinical validation of circulating tumor cell synaptophysin and androgen receptor expression in metastatic prostate cancer phenotypes.
[View Publication](https://doi.org/10.1200/JCO.2026.44.16_suppl.5041) [Video](https://www.youtube.com/watch?v=_oGC1KRVN2U) CyteFinder 2026
### Dr. Pashtoon Kasi on the impact of circulating tumor cells on clinical research
[Watch Video](https://www.youtube.com/watch?v=_oGC1KRVN2U) [Publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC12881594/) CyteFinder Nature Communications 2026
### Extracellular matrix mediates circulating tumor cell clustering in triple-negative breast cancer metastasis
[View Publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC12881594/) [Publication](https://doi.org/10.1016/j.ejso.2025.111357) CyteFinder European Journal of Surgical Oncology 2026
### Circulating tumor cells predict relapse in head and neck mucosal squamous cell carcinoma
[View Publication](https://doi.org/10.1016/j.ejso.2025.111357) [Publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC12805936/) CyteFinder Cancer Research Communications 2026
### Surface Marker Identification to Capture Live Circulating Tumor Cells in Metastatic Triple-Negative Breast Cancer
[View Publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC12805936/) [Publication](https://doi.org/10.3390/cancers17162717) CyteFinder Cancers 2025
### Comprehensive Longitudinal Linear Mixed Modelling of CTCs Illuminates the Role of Trop2, EpCAM, and CD45 in CTC Clustering and Metastasis
[View Publication](https://doi.org/10.3390/cancers17162717) [Publication](https://doi.org/10.1080/07366205.2025.2534299) CyteFinder BioTechniques 2025
### A novel device for buffy coat collection
[View Publication](https://doi.org/10.1080/07366205.2025.2534299) [Poster](https://cdn.sanity.io/files/s3p6uqps/production/246a94d07c9a47c844784f113f57f4415bf84a5c.pdf) CyteFinder 2025
### Development of a CTC Based Assay to Characterize MAOA Expression in Metastatic Prostate Cancer
[Download Poster](https://cdn.sanity.io/files/s3p6uqps/production/246a94d07c9a47c844784f113f57f4415bf84a5c.pdf) [Poster](https://cdn.sanity.io/files/s3p6uqps/production/43fb6d4a8510166e936d250b3bf172e2f669bfa3.pdf) CyteFinder 2025
### Quantitative analysis of HER2, HER3, and γH2AX expression on circulating tumor cells for pharmacodynamic measurement in clinical trials
[Download Poster](https://cdn.sanity.io/files/s3p6uqps/production/43fb6d4a8510166e936d250b3bf172e2f669bfa3.pdf) [Publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC11985722/) CyteFinder Cellular and Molecular Life Sciences 2025
### Portal venous circulating tumor cells as a biomarker for relapse prediction in resected pancreatic cancer
[View Publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC11985722/) [Publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC12092302/) CyteFinder Nature Medicine 2025
### Neoadjuvant triplet immune checkpoint blockade in newly diagnosed glioblastoma
[View Publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC12092302/) [Poster](https://cdn.sanity.io/files/s3p6uqps/production/f6e029d0a3ad855ff644046c0b1c1c20cf771df2.pdf) CyteFinder Orion 2024
### Next Gen Liquid Biopsy: Comprehensive Analysis from a Single Tube of Blood
[Download Poster](https://cdn.sanity.io/files/s3p6uqps/production/f6e029d0a3ad855ff644046c0b1c1c20cf771df2.pdf)